Integrative Clinical Trials

What Integrative Clinical Trials does

Integrative Clinical Trials is a private clinical research site founded in 2012 and based in Brooklyn, New York, focused on conducting clinical trials for nervous system (CNS) disorders. The site operates with 11-50 employees and serves pharmaceutical and biotechnology sponsors requiring access to a diverse metropolitan patient population and CNS-specific trial execution expertise. Its disclosed capabilities include running randomized, double-blind, placebo-controlled trial protocols, with one named engagement being the Phase 2 CALMA trial of IGC Pharma's cannabinoid-based investigational therapy IGC-AD1 for agitation associated with Alzheimer's disease.

The company's revenue model is not publicly disclosed; as a clinical trial site, it typically generates service revenue through per-patient fees, milestone payments, and protocol-based reimbursements negotiated with pharmaceutical sponsors. Its go-to-market depends on being selected into sponsor trial networks, which requires demonstrated CNS expertise, regulatory compliance, and patient recruitment capacity in the New York metropolitan area.

There is no disclosed proprietary technology platform, software product, or digital infrastructure in the input data, and the company has not announced funding rounds, acquisitions, or geographic expansion beyond its single Brooklyn office. Leadership includes CFO Leonid Chernoy, indicating formalization of finance functions, but no other management or scientific personnel are publicly identified in the available sources.

Name

Integrative Clinical Trials

Legal name

Integrative Clinical Trials

Website

https://iclinicaltrials.net

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Integrative Clinical Trials is a Brooklyn, NY-based clinical research site founded in 2012, specializing in CNS disorder trials for pharmaceutical and biotechnology sponsors, with 11-50 employees.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industry

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC)

Keywords

• Clinical trial site
• CNS clinical research
• Phase 2 trials
• Alzheimer's disease research
• Neurology clinical trials

Headquarters

HQ city

Brooklyn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure

Core offering

Integrative Clinical Trials operates a clinical research site in Brooklyn, New York, conducting nervous system disorder trials for pharmaceutical and biotechnology sponsors. The site provides infrastructure for randomized, double-blind, placebo-controlled clinical trials and access to a diverse metropolitan patient population, with particular expertise in CNS research such as Alzheimer's disease and agitation studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Site Services for CNS Disorders Site-based clinical trial execution services for pharmaceutical and biotechnology sponsors developing therapies for central nervous system (CNS) conditions, including the conduct of randomized, double-blind, placebo-controlled trials and patient recruitment from a diverse metropolitan population.
• Phase 2 CALMA Trial Site Participation Clinical site participation in IGC Pharma's Phase 2 CALMA trial evaluating IGC-AD1, a cannabinoid-based investigational therapy for agitation associated with Alzheimer's disease.

Named customers1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• IGC PharmacoreStrategic or Co-development PartnerIGC Pharma has added Integrative Clinical Trials in Brooklyn, New York as a new site for its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The new site strengthens the trial's clinical network by providing access to a diverse metropolitan patient population and CNS research expertise. IGC-AD1 is a cannabinoid-based investigational therapy being evaluated in a randomized, double-blind, placebo-controlled Phase 2 trial as the company's lead asset.

Scale indicators2 records

Recent moves2 records

Expansion highlights2 records

Broad incumbents

• Clinipace Worldwide: Mid-sized CRO offering clinical trial management and site coordination services across therapeutic areas. Comparable as a competitor and potential partner in the same clinical trial site services market.
• ICON plc: Global CRO providing clinical development and site-services across all phases. Operates in the same clinical trial services ecosystem and competes for sponsor site network allocations.
• Medpace: Mid-to-large global CRO that runs full-service clinical development programs and operates site relationships. Comparable as a downstream counterparty and competitor for sponsor trial outsourcing decisions affecting sites like Integrative Clinical Trials.
• IQVIA: World's largest CRO with extensive site network, technology platforms, and site-management capabilities. Competes broadly with independent SMOs for sponsor outsourced trial execution.

Emerging players

• WCG (WIRB-Copernicus Group): Provider of clinical trial site enablement services including IRB, technology, and site-support solutions. Adjacent peer in the clinical trial site ecosystem, supplying services used by site operators like Integrative Clinical Trials.

Direct peers

• Flourish Research: Multi-site clinical research site network operating dedicated Phase 1–4 trial facilities. Directly comparable as a clinical trial site operator serving pharmaceutical sponsors, though larger and multi-region versus Integrative Clinical Trials' single Brooklyn location.
• Accel Research Sites: Network of clinical research sites conducting Phase 2–4 trials across multiple therapeutic areas. Directly comparable as an independent clinical trial site operator competing for the same sponsor protocols as Integrative Clinical Trials.
• Meridian Clinical Research: Network of clinical research sites specializing in vaccine, CNS, and metabolic trial execution. Directly comparable as a CNS-experienced clinical trial site network, though materially larger in site count.
• Benchmark Research: Independent clinical trial site operator running multi-therapeutic trials for pharma/biotech sponsors. Comparable as a single- or multi-site SMO competing in the same clinical trial site services market.
• Optimal Research: Independent clinical trial site network conducting Phase 2–4 studies across therapeutic areas. Comparable as a site-management organization serving pharma sponsors with similar site-services delivery model.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Facebookfacebook.com/IntegrativeClinicalTrials
• LinkedInlinkedin.com/company/integrative-clinical-trials-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integrative Clinical Trials